上海鲸奇生物科技有限公司是一家创新型基因药物开发的高新科技企业。公司通过结合基因编辑技术和再生医学的方法，致力于重大神经系统疾病（如帕金森、阿尔兹海默症、中风、先天性失明等重大疾病）的基因药物开发，力争成为全球优秀的神经疾病基因药物研发企业。目前，因科学研究和业务拓展需求，我公司将招聘和培养一批高素质研究人员、管理人员和实验技术人员。 Genemagic Biosciences was founded in 2020, and headquartered in Kangqiao region, Shanghai. The company is developing regenerative medicines (via gene therapy) to treat neurological, ocular, and hearing diseases, and currently in preclinical stage. The key scientific founder, Dr. Haibo Zhou, is a Principal Investigator at China Academy of Science, with extensive experiences on the discovery of genome editing tools and neurological disease treatments, and has authored more than 10 research articles published on high profile scientific journals. Genemagic obtained seed investment from a reputable biotech VC, Kaitai Capital, in 2021.